We founded mbiomics to improve peoples lives by providing a novel approach to fully understand the secrets of the microbiome with the goal to better inform targeted therapies and how to lead a healthy life.
mbiomics has raised €12M across 1 funding round from 2 investors, most recently a Series A round in Apr 2026. Based in Munich, Germany; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-04-30 | Series A | €12M |
| Bayern Kapital,MIG Fonds |
| View deal → |
